Neuromyelitis optica (NMO) - an autoimmune disease of the central nervous system (CNS)

Acta Neurologica Scandinavica

Volumn 123, Issue 6, 2011, Pages 369-384

  Asgari, N ^a,b   Owens, T ^b   Frokiaer J ^c   Stenager, E ^a,b   Lillevang, S T ^d   Kyvik, K O ^b  

^a Sonderborg Hospital   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aquaporin 4 antibody; Aquaporins; Autoimmunity; Neuromyelitis optica; NMO IgG

Indexed keywords

AQUAPORIN 4; BIOLOGICAL MARKER; GLUTAMIC ACID; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY;

AFRICA; ALLERGIC ENCEPHALOMYELITIS; ANTIBODY BLOOD LEVEL; ASIAN; ASTROCYTE; AUTOIMMUNE DISEASE; BRAIN NECROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CHANNELOPATHY; DISEASE PREDISPOSITION; ETHNICITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOLOGY; IN VITRO STUDY; MYELOOPTIC NEUROPATHY; PATHOGENESIS; PHENOTYPE; REVIEW; TRANSGENIC MOUSE;

ANIMALS; AQUAPORIN 4; AUTOANTIBODIES; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; MICE, TRANSGENIC; NEUROMYELITIS OPTICA;

EID: 79954490726     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01416.x     Document Type: Review

References (113)

1. Barrera SE. Ophthalmo-encephalo-myelopathy. Psychiatr Q 1932;6:421-37.
2. Erb W. Ueber das zusammenvorkommen von Neuritis optica und Myelitis subacuta. Eur Arch Psychiatry Clin Neurosci 1880;10:146-57.
3. Devic E. Myelite subaigue compliquee de neurite optique. Bull Med 1894;8:1033-4.
4. Beck GM. A case of diffuse myelitis associated with optic neuritis. Brain 1927;50:687-703. Ref Type: Generic
5. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
6. Paul F, Jarius S, Aktas O et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007;4:e133.
7. Takahashi T, Fujihara K, Nakashima I et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-43.
8. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
9. Jacob A, Matiello M, Wingerchuk DM, Lucchinetti CF, Pittock SJ, Weinshenker BG. Neuromyelitis optica: changing concepts. J Neuroimmunol 2007;187:126-38.
10. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008;118:209-17.
11. Magana SM, Pittock SJ, Lennon VA, Keegan BM, Weinshenker BG, Lucchinetti CF. Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol 2009;66:964-6.
12. Miller DH, Weinshenker BG, Filippi M et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74.
13. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005;65:1479-82.
14. Matsuoka T, Matsushita T, Kawano Y et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007;130:1206-23.
15. Takahashi T, Miyazawa I, Misu T et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry 2008;79:1075-8.
16. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390-6.
17. Magana SM, Matiello M, Pittock SJ et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009;72:712-7.
18. Poppe AY, Lapierre Y, Melancon D et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005;11:617-21.
19. Vernant JC, Cabre P, Smadja D et al. Recurrent optic neuromyelitis with endocrinopathies: a new syndrome. Neurology 1997;48:58-64.
20. Blanc F, Zephir H, Lebrun C et al. Cognitive functions in neuromyelitis optica. Arch Neurol 2008;65:84-8.
21. Jarius S, Paul F, Franciotta D et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008;4:202-14.
22. Wingerchuk DM, Hogancamp WF, O'brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14.
23. Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68:603-5.
24. Collongues N, Marignier R, Zephir H et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010;74:736-42.
25. O'riordan JI, Gallagher HL, Thompson AJ et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60:382-7.
26. Wingerchuk DM. Diagnosis and treatment of neuromyelitis optica. Neurologist 2007;13:2-11.
27. Ghezzi A, Bergamaschi R, Martinelli V et al. Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica. J Neurol 2004;251:47-52.
28. Takagi M, Tanaka K, Suzuki T, Miki A, Nishizawa M, Abe H. Anti-aquaporin-4 antibody-positive optic neuritis. Acta Ophthalmol 2009;87:562-6.
29. Matsushita T, Matsuoka T, Isobe N et al. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 2009;73:171-6.
30. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology 2003;60:848-53.
31. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2003;2:117-27.
32. Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162-8.
33. Pittock SJ, Lennon VA, De SJ et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008;65:78-83.
34. Weinshenker BG, Wingerchuk DM, Vukusic S et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566-9.
35. De Seze J, Arndt C, Jeanjean L et al. Relapsing inflammatory optic neuritis: is it neuromyelitis optica? Neurology 2008;70:2075-6.
36. Matiello M, Lennon VA, Jacob A et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008;70:2197-200.
37. Weinshenker BG, Wingerchuk DM. Neuromyelitis optica: clinical syndrome and the NMO-IgG autoantibody marker. Curr Top Microbiol Immunol 2008;318:343-56.
38. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473-7.
39. Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J 2008;15:99-105.
40. Hayakawa S, Mori M, Okuta A et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008;196:181-7.
41. Nakashima I, Fujihara K, Miyazawa I et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry 2006;77:1073-5.
42. Cabre P, Heinzlef O, Merle H et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology 2001;56:507-14.
43. Mcalpine D. Familial neuromyelitis optica: its occurrence in identical twins. Brain 1938;61:430-48.
44. Ch'ien LT, Medeiros MO, Belluomini JJ, Lemmi H, Whitaker JN. Neuromyelitis optica (Devic's syndrome) in two sisters. Clin Electroencephalogr 1982;13:36-9.
45. Keegan M, Pineda AA, Mcclelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002;58:143-6.
46. Braley T, Mikol DD. Neuromyelitis optica in a mother and daughter. Arch Neurol 2007;64:1189-92.
47. Brynedal B, Duvefelt K, Jonasdottir G et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2007;2:e664.
48. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000;55:140-8.
49. Friese MA, Jakobsen KB, Friis L et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 2008;14:1227-35.
50. Kira J, Kanai T, Nishimura Y et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 1996;40:569-74.
51. Yamasaki K, Horiuchi I, Minohara M et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 1999;122(Pt 9):1689-96.
52. Furukawa Y, Yoshikawa H, Yachie A, Yamada M. Neuromyelitis optica associated with myasthenia gravis: characteristic phenotype in Japanese population. Eur J Neurol 2006;13:655-8.
53. Ito H, Yamasaki K, Kawano Y et al. HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese. Tissue Antigens 1998;52:179-82.
54. Agre P, King LS, Yasui M et al. Aquaporin water channels--from atomic structure to clinical medicine. J Physiol 2002;542:3-16.
55. Verkman AS. Knock-out models reveal new aquaporin functions. Handb Exp Pharmacol 2009;190:359-81.
56. Amiry-Moghaddam M, Lindland H, Zelenin S et al. Brain mitochondria contain aquaporin water channels: evidence for the expression of a short AQP9 isoform in the inner mitochondrial membrane. FASEB J 2005;19:1459-67.
57. Mylonakou MN, Petersen PH, Rinvik E et al. Analysis of mice with targeted deletion of AQP9 gene provides conclusive evidence for expression of AQP9 in neurons. J Neurosci Res 2009;87:1310-22.
58. Gorelick P, Sechenova O, Hennekens CH. Evolving perspectives on clopidogrel in the treatment of ischemic stroke. J Cardiovasc Pharmacol Ther 2006;11:245-8.
59. Yakata K, Hiroaki Y, Ishibashi K et al. Aquaporin-11 containing a divergent NPA motif has normal water channel activity. Biochim Biophys Acta 2007;1768:688-93.
60. Jung JS, Preston GM, Smith BL, Guggino WB, Agre P. Molecular structure of the water channel through aquaporin CHIP. The hourglass model. J Biol Chem 1994;269:14648-54.
61. Nielsen S, Nagelhus EA, Miry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997;17:171-80.
62. Tait MJ, Saadoun S, Bell BA, Papadopoulos MC. Water movements in the brain: role of aquaporins. Trends Neurosci 2008;31:37-43.
63. Venero JL, Vizuete ML, Machado A, Cano J. Aquaporins in the central nervous system. Prog Neurobiol 2001;63:321-36.
64. Owens T, Bechmann I, Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol 2008;67:1113-21.
65. Oshio K, Watanabe H, Song Y, Verkman AS, Manley GT. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1. FASEB J 2005;19:76-8.
66. Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS. Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J Clin Invest 1997;100:957-62.
67. Lu M, Lee MD, Smith BL et al. The human AQP4 gene: definition of the locus encoding two water channel polypeptides in brain. Proc Natl Acad Sci USA 1996;93:10908-12.
68. Yang B, Ma T, Verkman AS. cDNA cloning, gene organization, and chromosomal localization of a human mercurial insensitive water channel. Evidence for distinct transcriptional units. J Biol Chem 1995;270:22907-13.
69. Sorani MD, Zador Z, Hurowitz E, Yan D, Giacomini KM, Manley GT. Novel variants in human Aquaporin-4 reduce cellular water permeability. Hum Mol Genet 2008;17:2379-89.
70. Neely JD, Christensen BM, Nielsen S, Agre P. Heterotetrameric composition of aquaporin-4 water channels. Biochemistry 1999;38:11156-63.
71. Crane JM, Tajima M, Verkman AS. Live-cell imaging of aquaporin-4 diffusion and interactions in orthogonal arrays of particles. Neuroscience 2010;168:892-902.
72. Nicchia GP, Mastrototaro M, Rossi A et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009;57:1363-73.
73. Kleffner I, Bungeroth M, Schiffbauer H, Schabitz WR, Ringelstein EB, Kuhlenbaumer G. The role of aquaporin-4 polymorphisms in the development of brain edema after middle cerebral artery occlusion. Stroke 2008;39:1333-5.
74. Bodin P, Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res 1998;47:351-4.
75. Dubyak GR, El-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993;265:C577-606.
76. Weisman GA, Wang M, Kong Q et al. Molecular determinants of P2Y2 nucleotide receptor function: implications for proliferative and inflammatory pathways in astrocytes. Mol Neurobiol 2005;31:169-83.
77. Lee M, Lee SJ, Choi HJ et al. Regulation of AQP4 protein expression in rat brain astrocytes: role of P2X7 receptor activation. Brain Res 2008;1195:1-11.
78. Cavaliere F, Amadio S, Sancesario G, Bernardi G, Volonte C. Synaptic P2X7 and oxygen/glucose deprivation in organotypic hippocampal cultures. J Cereb Blood Flow Metab 2004;24:392-8.
79. Vincent T, Saikali P, Cayrol R et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008;181:5730-7.
80. Hinson SR, Roemer SF, Lucchinetti CF et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008;205:2473-81.
81. Bhat R, Steinman L. Innate and adaptive autoimmunity directed to the central nervous system. Neuron 2009;64:123-32.
82. Kinoshita M, Nakatsuji Y, Moriya M et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 2009;20:508-12.
83. Cloys DE, Netsky MG. Neuromyelitis optica. In: Viken PJ, Bruyn GW, eds. Handbook of clinical neurolog. Amsterdam: North-Holland, 1970;426-36.
84. Lucchinetti CF, Mandler RN, Mcgavern D et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002;125:1450-61.
85. Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006;63:964-8.
86. Misu T, Fujihara K, Kakita A et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007;130:1224-34.
87. Roemer SF, Parisi JE, Lennon VA et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007;130:1194-205.
88. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008;131:1464-77.
89. Kornek B, Storch MK, Weissert R et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000;157:267-76.
90. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993;14:426-30.
91. Jarius S, Franciotta D, Bergamaschi R et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007;68:1076-7.
92. Jarius S, Boul-Enein F, Waters P et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-80.
93. Bennett JL, Lam C, Kalluri SR et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617-29.
94. Kinoshita M, Nakatsuji Y, Kimura T et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 2009;386:623-7.
95. Bradl M, Misu T, Takahashi T et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-43.
96. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010;133:349-61.
97. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med 2003;197:1073-81.
98. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 2006;116:2393-402.
99. Li L, Zhang H, Verkman AS. Greatly attenuated experimental autoimmune encephalomyelitis in aquaporin-4 knockout mice. BMC Neurosci 2009;10:94.
100. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-2.
101. Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007;46:1671-2.
102. Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr Neurol Neurosci Rep 2008;8:427-33.
103. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27:79-85.
104. Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 2009;9:10-25.
105. Jacob A, Weinshenker BG, Violich I et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-8.
106. Chan KH, Ramsden DB, Yu YL et al. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. Eur J Neurol 2009;16:310-6.
107. Mckeon A, Lennon VA, Jacob A et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009;39:87-90.
108. Gokcay F, Celebisoy N, Gokcay A, Kabasakal Y, Oder G. Primary Sjogrens syndrome presenting as neuromyelitis optica. Pediatr Neurol 2007;36:58-60.
109. Fridkis-Hareli M. Immunogenetic mechanisms for the coexistence of organ-specific and systemic autoimmune diseases. J Autoimmune Dis 2008;5:1.
110. Wu JS, Zhang MN, Carroll WM, Kermode AG. Characterisation of the spectrum of demyelinating disease in Western Australia. J Neurol Neurosurg Psychiatry 2008;79:1022-6.
111. Rivera JF, Kurtzke JF, Booth VJ, Corona VT. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol 2008;255:710-5.
112. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
113. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15.